# Tolerability, Safety and Pharmacokinetic Study of Humanized Anti-CD6 Monoclonal Antibody Injection in Chinese Psoriasis

> **NCT02649270** · PHASE1 · TERMINATED · sponsor: **Biotech Pharmaceutical Co., Ltd.** · enrollment: 11 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **BIOLOGICAL:** T1h

## Key facts

- **NCT ID:** NCT02649270
- **Lead sponsor:** Biotech Pharmaceutical Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-10
- **Primary completion:** 2015-06
- **Final completion:** 2017-10
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** company strategy
- **Last updated:** 2023-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02649270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02649270, "Tolerability, Safety and Pharmacokinetic Study of Humanized Anti-CD6 Monoclonal Antibody Injection in Chinese Psoriasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02649270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*